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http://dx.doi.org/10.1016/j.pedneo.2Pompe disease (glycogen storage disease type II or acid maltase deficiency) is a lysosomal dis-
order in which acid a-glucosidase (GAA) deficiencies lead to intralysosomal accumulation of
glycogen in all tissues; most notably in skeletal muscles. Both the patient’s age at the onset
of Pompe disease symptoms and the rate of deterioration caused by the disease can vary
considerably. In classical infant-onset Pompe disease (IOPD), symptoms start very early in life,
and death occurs soon afterward if the disease remains untreated. In later-onset Pompe dis-
ease, symptoms are slower to appear, and patients often progress to wheelchair confinement
and eventual respiratory failure. A diagnosis can be made by screening for GAA in dried blood
samples, followed either by GAA assessment in lymphocytes or in fibroblasts or by the genetic
analysis of mutations. Treatment by enzyme replacement therapy (ERT) with alglucosidase
alfa was approved for human use in 2006. In classical IOPD, treatment significantly lengthens
survival and improves motor development and cardiac function. The sooner ERT begins, the
better are the results. Newborn screening aims to take advantage of different technologies
for diagnosing and treating newborns early on and it yields better outcomes. However, new-
borns diagnosed early and other long-term survivors may encounter fresh problems, making
up a new phenotype of IOPD patients. Further modifications of the treatment, such as a
decrease in immune responses to ERT, a higher dosage, a better uptake formulation, and gene
therapy delivered locally or systemically are being explored.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.of Pediatrics and Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan.
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220 Y.-H. Chien et al1. Introduction
Pompe disease (glycogen storage disease type II or acid
maltase deficiency) is a lysosomal disorder in which acid a-
glucosidase (GAA) deficiencies lead to intralysosomal ac-
cumulations of glycogen in all tissues; most notably in
skeletal muscles.1 Pompe disease was first described by Dr.
J. C. Pompe in a 7-month-old girl with cardiomyopathy, in
whom massive accumulations of glycogen in vacuoles were
observed in all tissues examined.2 After de Duve identified
lysosomes in 1963,3 Pompe disease became the first
recognized lysosomal storage disorder (LSD). Currently,
enzyme replacement therapy (ERT) with recombinant
human GAA (rhGAA) is the only specific treatment for
Pompe disease.4,52. Classification
Clinically, Pompe disease presents as a wide spectrum of
phenotypes, ranging from the severe, rapidly progressive
infantile form that usually results in hypertrophic cardio-
myopathy, to the slowly progressing later-onset forms that
can occur anytime from early childhood to late adulthood
and typically present without cardiac manifestations. In
classical infantile-onset Pompe disease (IOPD), symptoms
start very early in life (at a median age of 2 months) and
death occurs soon afterward if the disease remains un-
treated (by a median age of 8.7 months).6 In later-onset
Pompe disease (LOPD), symptoms are slower to appear
and patients often progress to wheelchair confinement and
eventual respiratory failure.7 Nevertheless, the clinical
course in LOPD varies significantly e the age at diagnosis
ranges from <1 year to 78 years, and the age at symptom
onset from <1 year to 52 years in Caucasians.8 In the Chi-
nese population, the median age at symptom onset is 15
(12e35) years, and the median age at diagnosis 21 (10e38)
years; at the time of diagnosis or shortly thereafter, 53% of
patients require mechanical ventilation.93. Incidence
Pompe disease incidence appears to vary by ethnicity and
geography. The rapidly progressing infantile-onset form has
an estimated frequency of 1:138,000 in Caucasian pop-
ulations,10 1:50,000 among Chinese populations,11 and
1:14,000 among those of African ancestry.1 Notably, a high
prevalence of the disease in Arab populations has also been
noted.12 The incidence of the disorder estimated from
carrier frequencies obtained in New York is 1: 40,000,13
which is similar to the birth prevalence of the combined
adult and infantile phenotypes in Netherlands.14
However, these numbers are primarily based on pre-
dictions from carrier frequencies and retrospectively
registered data. The development of newborn screening for
Pompe disease provides another chance to estimate inci-
dence. The first pilot project started in Taiwan measured
GAA activity in dried blood spots (DBSs)15 using fluorescent
substrates, followed by confirmation via mutation analysis
for samples with suspected enzyme deficiencies.16 The
incidence for IOPD is 1 in 52,000 and the combinedincidence for both IOPD and LOPD is 1 in 17,000.17 Another
pilot project conducted in Austria measured DBS GAA ac-
tivity and subsequently confirmed via mutation analysis for
samples with suspected enzyme deficiencies. In that study,
the incidence of the disease was 1 in 8,684 newborns.18 The
discrepancies between these results and clinical observa-
tions may be explained by a trend of underdiagnosing
Pompe disease or by very mild presentations lacking clinical
significance. The discrepancies between these results and
the predictions from carrier frequencies may be explained
by the polymorphic nature of the GAA gene, meaning that
the frequencies of selective variants may underestimate
the true incidence of Pompe disease.4. Genes
The GAA gene is located on chromosome 17q25. The gene is
w28 kb long and contains 20 exons. The first exon is not
translated and is separated by an w2.7-kb intron from the
second exon. The gene encodes a peptide of 952 amino
acids with a molecular weight of 110 kDa. Extensive protein
modifications occur post-translationally, including glyco-
sylation and proteolytic processing, resulting in the 76-kDa
and 70-kDa mature GAA proteins.19 More than 250 muta-
tions have been found on the GAA gene,20 and the muta-
tions are spread over the gene. Several common mutations
are found in different ethnic groups, including the c.-32-
13T>G splicing mutation in Caucasian patients,21 the
p.R854X mutation in African Americans,1 and the p.D645E
mutation in Chinese patients from Taiwan.22 A few of the
mutations have been expressed in cultured cells, and the
observed GAA activities can be correlated to phenotypes or
to disease severity.23
Mutations in Chinese ethnicities, such as those found in
people living in Taiwan, are different from those of Cau-
casians. For instance, the mutation p.D645E, which has
been observed in up to 80% of infantile cases, is associated
with a haplotype, suggesting a founder effect.24 The mu-
tation p.W746C is associated with LOPD.9 There are two
other sequence variations that are even more frequent
among Asian populations, including populations in Taiwan
and Japan:25 p.G576S and p.E689K. These two variations
were found to be homozygous in one patient who died of
cardiac failure at 14 years of age, with Pompe disease being
diagnosed due to low GAA activity (11e15% of residual GAA
activity).26 Variation p.E689K was later reported to be a
neutral polymorphism,27 but the role of p.G576S remained
intriguing because that particular patient had no glycogen
storage in his skeletal muscles. By transient transfection in
COS-7 cells, GAA activity for p.G576S was 20% compared
with the wild-type construct,28 which led to the categori-
zation of variation p.G576S as a “pseudodeficiency”.26
The pseudodeficiency allele p.G576S has at least two
important aspects: (1) it creates a severe background for
other mutations; and (2) it produces a high false-positive
rate in newborn screening that relies on GAA activity
measurements. Residue 576 of the GAA protein is a
conserved codon, but the glycine to serine change is non-
conserved. Although it displays normal apparent Km values
and causes only small conformational changes,26 pre-
dictions by the support vector machine models29,30 imply
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relates with decreased levels of enzyme protein.26 For this
reason, p.G576S may modify other mutations in cis. For
example, the mutation p.D645E was found in an adult
AfricaneAmerican patient31 who lacked the p.G576S vari-
ation32 and therefore presented with a milder phenotype.
Mutation p.W746C shows only 8% of normal GAA activity in
transfected fibroblasts, whereas the p.[W746C; G576S]
mutation fails to yield detectable GAA activity (0.3% of
normal, p Z 0.029).9 We have coexpressed several other
mutations with p.G576S, and all of them have shown
decreased GAA activity due to the presence of p.G576S
(Figure 1).
The allele frequency of the pseudodeficiency allele
p.G576S in the Taiwanese population is 14.5% (94 in 650
chromosomes)17; a far higher frequency than is found
among European and sub-Saharan/African populations.28
An estimated 3.3e3.9% of people in Asian populations are
homozygous,25,28 which is consistent with our finding of
3.69%.17 However, to the best of our knowledge, none of
those homozygous individuals have been confirmed as
having Pompe disease.23,28 Previously, we performed gen-
otyping analyses for 99 false-positive samples identified
during Pompe newborn screening; all of which possessed at
least one pseudodeficiency allele (allele frequency:
84.8%).32 We also analyzed 325 anonymous random
newborn blood spots for p.G576S and correlated the find-
ings with the GAA activity.17 The results revealed that the
mean GAA activity for the p.G576/p.G576 genotype was
16.96  5.64 mmol/L/h (n Z 243); for p.G576/p.S576, it
was 9.55  3.86 mmol/L/h (nZ 70); and for p.S576/p.S576,
it was 5.84  3.68 mmol/L/h (n Z 12). We observed that
p.G576S was strongly associated with low GAA activity
(p < 0.001). The 12 samples that were homozygous for
p.G576S had GAA activities of 1.43e11.86 mmol/L/h
(8.81e72.85% of the normal mean). These results reveal
that the prevalence of the pseudodeficiency allele posesFigure 1 Enzyme activity of the mutant forms of acid a-
glucosidase (GAA). Activity of GAA from transfected COS-1 cells
was measured by the 4-MU substrate in triplicate, and the
average  standard deviation GAA activity is reported. The
activity of GAA measured by the glycogen substrate was
measured in duplicate, and the average  standard deviation
GAA activity is reported.significant challenges for screening newborns for Pompe
disease, particularly in Taiwan.
5. Laboratory Diagnosis
Laboratory diagnosis depends on the measurement of GAA
activity in blood or tissues. Theoretically, patients with
IOPD have very low residual GAA activity, whereas those
with LOPD (juvenile- or adult-onset Pompe disease) have
higher residual GAA activity. The assay used to measure
GAA activity usually uses an artificial fluorogenic substrate,
4-methylumbelliferyl-a-D-glucopyranoside (4-MUG), but
several a-glucosidase (E.C. 3.2.1.20) isoenzymes in the
blood cells, especially maltase glucoamylase (MGA),
contribute to the observed reaction.1,33,34 Therefore, only
through adequate lymphocyte separation, the use of skin
fibroblasts in the assay,33,35 or the combined use of either
immobilized antibodies36 or MGA inhibitors37,38 can residual
GAA activity be measured accurately. Recently, using mixed
leukocytes instead of lymphocytes to diagnose Pompe dis-
ease has been proposed.39 With the help of suitable MGA
inhibitors (acarbose) in the assays with the fluorometric
substrate at pH 4.0, they can specifically measure lyso-
somal GAA activity.39 However, the assay still has problems
differentiating pseudodeficiency from true patients, such
as those with LOPD.
The advantages of new techniques may speed the dis-
covery of GAA mutations in individuals. However, as pre-
viously noted, this gene is highly polymorphic, and many
novel variations are still being discovered.20,32 For
example, in our study, after genotyping 107 babies who had
low DBS GAA activity, it was demonstrated that 69 (64.5%)
babies had a total of 54 mutations, with 35 novel predict-
ably pathogenic mutations.32 Further prediction methods,
such as model reconstruction, most likely are not sufficient
for the purposes of diagnosis and genetic counseling if they
are not coupled with good GAA activity measurements,
especially in the setting of presymptomatic screening, such
as newborn screening.
6. Treatment
The instant treatment for enzyme deficiencies is ERT using
human GAA. Recombinant GAA protein has been developed
independently by several groups, including one using re-
combinant GAA purified from rabbit milk40 and another
using protein expression methods with CHO cells.41 Both
products degrade lysosomal glycogen in the heart and
muscle.4,5 Decreases in heart size are usually observed 3
months after treatment has been initiated (Figure 2). In a
study with a cohort who received ERT prior to the age of 6
months without respiratory insufficiency, all patients sur-
vived to 18 months of age after 52 weeks of treatment.5 A
Cox proportional hazards analysis demonstrated that
treatment decreased the risk of death by 99%. The US Food
and Drug Administration (FDA) approved the use of
Myozyme (alglucosidase alfa) for IOPD in 2006. Studies on
LOPD have been completed,42 and the results show that
ERT can maintain muscular function and improve quality of
life, which has led to the approval of Lumizyme by the FDA
in 2010 for use in LOPD. Treatment should be started early,
Figure 2 Reversal of cardiomegaly in a patient with infant-onset Pompe disease (IOPD). (A) Four chamber view and (B) short-axis
view of a two-dimensional echocardiogram from a 1-month-old male infant with IOPD. BLZ baseline; MZ month after treatment.
Pictures are courtesy of Dr. Chu-Ann Chen.
222 Y.-H. Chien et alprior to the destruction of muscle architecture, for suc-
cessful outcomes.4,43
High doses of the recombinant enzyme are required for a
positive response. For example, in a quail study, the effects
of high-dose treatment (14 mg/kg) were much better than
those with low-dose treatment (4.2 mg/kg).44 The current
market dosage is 20 mg/kg via infusion every other week.
This is much higher than the dose used for other LSDs(laronidase 0.58 mg/kg every week for mucopolysacchar-
idosis I, agalsidase b 1 mg/kg every other week for Fabry
disease, and imiglucerase or velaglucerase alfa 60 IU/kg
every other week for Gaucher disease); the reason why this
high dose of the enzyme is required in Pompe disease is not
fully known. One possible explanation is that the paucity of
mannose-6-phosphate receptors in the muscle tissues pre-
vents efficient uptake of the enzyme. The current dosage
Review of Pompe disease 223was set because in a Phase III clinical trial no clear advan-
tage emerged from giving 40 mg/kg over 20 mg/kg.5
Nevertheless, most IOPD patients now take 40 mg/kg
instead of the standard 20 mg/kg dose.45 Higher doses may
cause problems, such as the development of nephrotic
syndrome in patients receiving a daily infusion of 10 mg/kg
rhGAA,46 a higher risk of infusion-associated reactions 5
including life-threatening anaphylactic reactions, and
higher antibody production.5
Antibody formation against therapeutic proteins has
been well described in various LSDs, including Pompe dis-
ease.5 Anti-rhGAA IgG antibodies develop in all treated
patients, and most patients may tolerate this protein. The
titer typically surges quickly after the initial exposure, with
a median time to peak titer of 12 weeks after seroconver-
sion, which declines slowly thereafter.42,47 Work on IOPD
has clearly demonstrated a negative impact of sustained
high antibody titers on ERT outcomes e for example,
patients with cross-reactive immunological material
(CRIM)-negative status are usually associated with poor
outcomes.47Figure 3 Chest X-ray of a 1-day-old female newborn.7. Newborn Screening
Clinical diagnosis of Pompe disease is usually delayed for
several months or years,6,9 therefore, newborn screening
provides a chance for early diagnosis and treatment,
especially for IOPD. We initiated a newborn screening
program for Pompe disease in 2005, measuring GAA activity
in DBSs via a fluorescence assay.15 Up until the end of 2011,
>470,000 newborns were screened,17 and nine IOPD new-
borns received their first ERT prior to the age of 1 month.
Applying a suitable control enzyme such as neutral a-
glucosidase can improve the performance of newborn
screening. From our data, using the neutral a-glucosidase/
GAA ratio had a positive predictive value of 63.4% and a
false-positive rate of 0.003%, whereas missing only two
cases of suspected LOPD gave a false-negative rate of
7.1%.17 Adding the percentage of acarbose inhibition as a
second-tier test for those with inconclusive results can
improve the positive predictive value to 92.9%.17
Other platforms have also been developed and tested in
large screening programs. Enzyme activity measurement
using a tandem-mass-spectrometry-based assay for Pompe
disease can be performed simultaneously with other lyso-
somal enzyme assays in a separate reaction18 or even in the
same reaction mixtures.48 However, the method still needs
solutions to countenance the interference of pseudodefi-
ciency. Another multiplex method involves applying a
multiplex microbead assay technology49 to measure the
amount of enzyme protein present in the sample. There is a
small possibility that a patient may present with a near-
normal amount of mutant enzyme protein, therefore, the
addition of an activity measurement in the same assay has
been developed and is waiting for scaled-up production of
the reagents involved. A new digital microfluidic method
that utilizes a disposable microchip has been designed for
simultaneous assaying of multiple lysosomal enzymes and
also uses the fluorometric substrate.50 It has been tested in
a pilot study in Illinois, USA, but has been suspended due to
the difficulties of scaling up production.Through newborn screening, patients can be treated
soon after birth. In the extension open-label rhGAA study
with the same cohort who received ERT prior to the age of
6 months without respiratory insufficiency, the survival
rate was better than those who received ERT after the age
of 6 months.43,51 In the first cohort, the proportion of pa-
tients alive with a ventilation-free survival rate was 66.7%
(95% confidence interval: 44.9e88.4%) at 24 months of age
and 49.4% (95% confidence interval: 26.0e72.8%) at 36
months of age.51 This is far greater than the overall sur-
vival rate of untreated and late-treated patients, but it is
still not satisfactory. We further demonstrated that
through newborn screening, 100% of patients remain
ventilation-free and alive.52 The five infants who had early
cardiac involvement demonstrated normalization of car-
diac size and muscle pathology with normal physical
growth and age-appropriate gains in motor development.52
Results from our study indicate that early treatment can
benefit infants with Pompe disease and highlight the ad-
vantages of early diagnosis, which can be achieved by
newborn screening.8. Problems of Long-term Survivors
Long-term survivors may encounter other problems. From
data describing primarily clinically diagnosed patients, less
than half of the patients were independently ambulatory.45
ERT reverses cardiomyopathy53 and global function54 but
still presents risks of arrhythmia.55 ERT improves motor
function51 but with incomplete correction in skeletal mus-
cles. Residual muscle weakness can include generalized
weakness/hypotonia, decreased endurance, and persistent
fatigue with selective weakness.56 Other weaknesses, such
as gastroesophageal reflux45 and ptosis,45 are also common.
It has been noted that glycogen accumulates in the central
nervous system (CNS) of Pompe patients,57e59 and because
the addition of recombinant enzyme into the systemic cir-
culation does not effectively cross the bloodebrain barrier,
224 Y.-H. Chien et alit therefore cannot reverse GAA deficiency in the CNS.60
Neurological dysfunction in Pompe disease continues to
be reported, but it is difficult to tell if it originates from
muscle weakness or from neurological deficits. These
problems include hearing loss due to a problem in the co-
chlea or middle ear,4,45,61 hypernasal speech with a flaccid
dysarthria and aspiration risk,62,63 and delays or de-
ficiencies in brain myelination61,64 that may be related to
delays in processing speed. Further studies to dissect
neurological components from muscle components may
help design better treatments.
Significant hypertrophic cardiomyopathy has been noted
in newborns (Figure 3), therefore, the storage process must
start prenatally. The storage may proceed to finally
damaging the cells through unknown factors, such as
autophagy activation.65 According to a model of staged
muscle damage, muscle cells can be classified from stage 1
(initial) to stage 5 (terminal).66 Landmarks in the staging
include the appearance of intralysosomal or cytoplasmic
glycogen, the integrity of the mitochondria, and myofibril
dissociation. Muscle cells may not be able to recover if ERT
is begun at stage 4 or 5. Therefore, it is not surprising that
newborns with early treatment (starting ERT prior to the
age of 1 month) have even better outcomes. However, the
long-term phenotypes in patients treated so early are not
yet well demonstrated.1 
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Figure 4 Antibody and protein status in Taiwanese patients. (A) A
patients who received rhGAA infusion regularly. Two patients never
analysis of fibroblast (1,2,4-7) and lymphocyte (3) GAA protein for9. Future Aspects in Therapy
Patients with high, sustained antibody titers have a dimin-
ished response to ERT.47 The use of immunomodulation to
maintain theeffects of rhGAA is currently beingexploredwith
some success.67,68 Usually CRIM-negative Pompe patients
develop high-titer antibodies to the rhGAA.47 In most cases,
CRIM status can be predicted from the GAA mutations.69 In
Taiwan, p.D645E is a common mutation. Cells with this mu-
tation synthesize the precursor normally but have abnormal
transportation, phosphorylation, and proteolytic process-
ing,70 so patients with this mutation should be CRIM-positive,
indicating lower risks of developing high sustained antibody
titers and thus securing a better outcome. Our patients
receiving ERT have developed antibodies against rhGAA but
have developed toleration later, and all of our patients have
expressed the precursor GAA protein (Figure 4A and B).
From theanimal and clinical data, ERT ismore effective at
addressing cardiomyopathy and is less effective at treating
skeletal muscle damage; higher dosages of rhGAA or
improving the uptake of rhGAA are two examples of ways to
improve the outcomes in muscle tissues. Higher dosages of
rhGAA have been tested in humans but there is no clear
conclusion about the clinical benefit.51 The uptake of rhGAA
is mediated through the cation-independent mannose-6-
phosphate receptor (CI-MPR) so that binding mannose-6-1    
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Review of Pompe disease 225phosphorylated glycan (M6P) on the rhGAA protein surface
triggers receptor-mediated endocytosis and delivers the
extracellular rhGAA to the lysosomes. One approach that has
been used to enhance the uptake of rhGAA is conjugation of
bis-M6P-containing oligosaccharides to rhGAA. This neo-
rhGAA displays an increase in cellular uptake in vitro and
in vivo and an increase in glycogen clearance from Pompe
mouse muscle tissue.71 The second approach uses a peptide-
based, glycosylation independent lysosomal targeting (GILT)
approach to create an rhGAA molecule containing a high-
affinity ligand for the CI-MPR.72 This GILT-tagged rhGAA was
significantly more effective than rhGAA at clearing glycogen
from numerous skeletal muscle tissues in the Pompe mouse
model,73 and a Phase II clinical trial is ongoing (www.
clinicaltrial.gov).
The disadvantages of ERT are the requirement for
frequent intravenous infusions of the recombinant enzyme
and the inability to reverse storage in the nervous system.
Treatment with small molecule pharmacological chaper-
ones not only could kinetically accelerate the protein
folding process and promote translocations of mutant en-
zymes, but also could potentiate the effects of rhGAA.74 It
can be administered orally. It has been shown that
chaperoning improves rhGAA stability in vitro and in vivo
and more effectively reduces glycogen in heart and skeletal
muscle in a Pompe mouse model compared with those using
rhGAA alone.75,76 A Phase II clinical study has been initiated
to investigate the effects of coadministered chaperones on
rhGAA in Pompe patients (www.clinicaltrial.gov).
Gene therapy for Pompe disease has been attempted to
correct simultaneously all affected tissues. Systemic
correction of the muscle disorder glycogen storage disease
type II has been tested in mice by hepatic targeting of a
modified adenovirus vector encodinghumanGAA77; however,
adenoviruses cause toxicity in humans. Intravenous injection
of therapeutic muscle-restricted recombinant adeno-
associated virus (rAAV) 2/8 or rAAV2/9 vectors significantly
reduced the glycogen content in striated muscle and the
diaphragm at 4.5 months post-treatment.78 Transplantation
of lentivirus-vector-mediated GAA-expressing hematopoiet-
ic stem cells has been shown to have therapeutic efficacy in
Pompe mice,79 which may be a feasible alternative method
aiming at systemic correction of the disease by gene/cell
combined therapy. However, there is still no evidence that
these treatments can be translated into human trials.
The CNS pathology in Pompe disease could also be
locally treated with gene transfer methods. For example,
direct administration of rAAV2/1 to the diaphragm of an
adult Gaa/ mouse is associated with increased efferent
phrenic nerve activity in addition to diaphragm biochemical
and functional correction, suggesting that rAAV-mediated
gene therapy can also modulate CNS activity in Pompe
disease.80 An open label, Phase I/II study administering
rAAV2/1-CMV-hGAA by direct intramuscular injection to the
diaphragm of Pompe human subjects has been initiated
(www.clinicaltrial.gov).References
1. Hirschhorn R, Reuser A. Glycogen storage disease type II: acid
alpha-glucosidase (acid maltase) deficiency. In: Scriver C,Beaudet A, Sly W, Valle D, editors. The metabolic and mo-
lecular bases of inherited disease. New York: McGraw-Hill;
2001. p. 3389e420.
2. Pompe J-C. Over idiopatische hypertrophie van het hart. Ned
Tijdshr Geneeskd 1932;76:304. (In Dutch).
3. De Duve C. The lysosome. Sci Am 1963;208:64e72.
4. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De
Klerk JB, Loonen MC, et al. Long-term intravenous treatment
of Pompe disease with recombinant human alpha-glucosidase
from milk. Pediatrics 2004;113:e448e57.
5. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL,
et al. Recombinant human acid [alpha]-glucosidase: major
clinical benefits in infantile-onset Pompe disease. Neurology
2007;68:99e109.
6. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D,
et al. A retrospective, multinational, multicenter study on the
natural history of infantile-onset Pompe disease. J Pediatr
2006;148:671e6.
7. Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC,
Reuser AJ, et al. Clinical manifestation and natural course of
late-onset Pompe’s disease in 54 Dutch patients. Brain 2005;
128:671e7.
8. Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JL, Phipps M,
DeRisoM,etal.Broad spectrumofPompedisease inpatientswith
the same c.-32-13T->G haplotype. Neurology 2007;68:110e5.
9. Yang CC, Chien YH, Lee NC, Chiang SC, Lin SP, Kuo YT, et al.
Rapid progressive course of later-onset Pompe disease in
Chinese patients. Mol Genet Metab 2011;104:284e8.
10. Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA,
Wokke JH, et al. Frequency of glycogen storage disease type II
in The Netherlands: implications for diagnosis and genetic
counselling. Eur J Hum Genet 1999;7:713e6.
11. Lin CY, Hwang B, Hsiao KJ, Jin YR. Pompe’s disease in Chinese
and prenatal diagnosis by determination of alpha-glucosidase
activity. J Inherit Metab Dis 1987;10:11e7.
12. Bashan N, Potashnik R, Barash V, Gutman A, Moses SW.
Glycogen storage disease type II in Israel. Isr J Med Sci 1988;
24:224e7.
13. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y,
Rom WN, et al. Carrier frequency for glycogen storage disease
type II in New York and estimates of affected individuals born
with the disease. Am J Med Genet 1998;79:69e72.
14. Ausems MG, ten Berg K, Kroos MA, van Diggelen OP,
Wevers RA, Poorthuis BJ, et al. Glycogen storage disease type
II: birth prevalence agrees with predicted genotype fre-
quency. Community Genet 1999;2:91e6.
15. Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC,
et al. Early detection of Pompe disease by newborn screening
is feasible: results from the Taiwan screening program. Pe-
diatrics 2008;122:e39e45.
16. Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL.
Later-onset Pompe disease: early detection and early treat-
ment initiation enabled by newborn screening. J Pediatr
2011;158:1023e1027.e1.
17. Chiang SC, Hwu WL, Lee NC, Hsu LW, Chien YH. Algorithm for
Pompe disease newborn screening: results from the taiwan
screening program. Mol Genet Metab 2012;106:281e6.
18. Mechtler TP, Stary S, Metz TF, De Jesu´s VR, Greber-Platzer S,
Pollak A, et al. Neonatal screening for lysosomal storage
disorders: feasibility and incidence from a nationwide study in
Austria. Lancet 2012;379:335e41.
19. Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J,
Reuser AJ. Structural and functional changes of lysosomal
acid alpha-glucosidase during intracellular transport and
maturation. J Biol Chem 1993;268:2223e31.
20. Kroos M, Hoogeveen-Westerveld M, Michelakakis H,
Pomponio R, Van der Ploeg A, Halley D, et al. Update of the
Pompe disease mutation database with 60 novel GAA
226 Y.-H. Chien et alsequence variants and additional studies on the functional
effect of 34 previously reported variants. Hum Mutat 2012;
33:1161e5.
21. Boerkoel CF, Exelbert R, Nicastri C, Nichols RC, Miller FW,
Plotz PH, et al. Leaky splicing mutation in the acid maltase
gene is associated with delayed onset of glycogenosis type II.
Am J Hum Genet 1995;56:887e97.
22. Ko TM, Hwu WL, Lin YW, Tseng LH, Hwa HL, Wang TR, et al.
Molecular genetic study of Pompe disease in Chinese patients
in Taiwan. Hum Mutat 1999;13:380e4.
23. Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ.
The genotype-phenotype correlation in Pompe disease. Am J
Med Genet C Semin Med Genet 2012;160:59e68.
24. Shieh JJ, Lin CY. Frequent mutation in Chinese patients with
infantile type of GSD II in Taiwan: evidence for a founder
effect. Hum Mutat 1998;11:306e12.
25. Shigeto S, Katafuchi T, Okada Y, Nakamura K, Endo F,
Okuyama T, et al. Improved assay for differential diagnosis
between Pompe disease and acid alpha-glucosidase pseudo-
deficiency on dried blood spots. Mol Genet Metab 2011;103:
12e7.
26. Tajima Y, Matsuzawa F, Aikawa S, Okumiya T, Yoshimizu M,
Tsukimura T, et al. Structural and biochemical studies on
Pompe disease and a “pseudodeficiency of acid alpha-gluco-
sidase”. J Hum Genet 2007;52:898e906.
27. Huie ML, Menaker M, McAlpine PJ, Hirschhorn R. Identification
of an E689K substitution as the molecular basis of the human
acid alpha-glucosidase type 4 allozyme (GAA*4). Ann Hum
Genet 1996;60:365e8.
28. Kroos MA, Mullaart RA, Van Vliet L, Pomponio RJ, Amartino H,
Kolodny EH, et al. p.[G576S; E689K]: pathogenic combination
or polymorphism in Pompe disease? Eur J Hum Genet 2008;16:
875e9.
29. Yue P, Li Z, Moult J. Loss of protein structure stability as a
major causative factor in monogenic disease. J Mol Biol 2005;
353:459e73.
30. Yue P, Moult J. Identification and analysis of deleterious
human SNPs. J Mol Biol 2006;356:1263e74.
31. Hermans MM, Wisselaar HA, Kroos MA, Oostra BA, Reuser AJ.
Human lysosomal alpha-glucosidase: functional character-
ization of the glycosylation sites. Biochem J 1993;289:681e6.
32. Labrousse P, Chien YH, Pomponio RJ, Keutzer J, Lee NC,
Akmaev VR, et al. Genetic heterozygosity and pseudodefi-
ciency in the Pompe disease newborn screening pilot pro-
gram. Mol Genet Metab 2010;99:379e83.
33. Taniguchi N, Kato E, Yoshida H, Iwaki S, Ohki T, Koizumi S.
Alpha-glucosidase activity in human leucocytes: choice of
lymphocytes for the diagnosis of Pompe’s disease and the
carrier state. Clin Chim Acta 1978;89:293e9.
34. Shin YS, Endres W, Unterreithmeier J, Rieth M, Schaub J.
Diagnosis of Pompe’s disease using leukocyte preparations.
Kinetic and immunological studies of 1,4-alpha-glucosidase in
human fetal and adult tissues and cultured cells. Clin Chim
Acta 1985;148:9e19.
35. Umapathysivam K, Hopwood JJ, Meikle PJ. Correlation of acid
alpha-glucosidase and glycogen content in skin fibroblasts
with age of onset in Pompe disease. Clin Chim Acta 2005;361:
191e8.
36. Umapathysivam K, Whittle AM, Ranieri E, Bindloss C,
Ravenscroft EM, van Diggelen OP, et al. Determination of acid
alpha-glucosidase protein: evaluation as a screening marker
for Pompe disease and other lysosomal storage disorders. Clin
Chem 2000;46:1318e25.
37. Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C.
Glycogen storage disease type II: enzymatic screening in dried
blood spots on filter paper. Clin Chim Acta 2004;347:97e102.
38. Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F,
et al. Direct multiplex assay of lysosomal enzymes in driedblood spots for newborn screening. Clin Chem 2004;50:
1785e96.
39. Okumiya T, Keulemans JL, Kroos MA, Van der Beek NM,
Boer MA, Takeuchi H, et al. A new diagnostic assay for
glycogen storage disease type II in mixed leukocytes. Mol
Genet Metab 2006;88:22e8.
40. Bijvoet AG, Kroos MA, Pieper FR, de Boer HA, Reuser AJ, van
der Ploeg AT, et al. Expression of cDNA-encoded human acid
alpha-glucosidase in milk of transgenic mice. Biochim Biophys
Acta 1996;1308:93e6.
41. Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT. High-level
production of recombinant human lysosomal acid alpha-
glucosidase in Chinese hamster ovary cells which targets to
heart muscle and corrects glycogen accumulation in fibro-
blasts from patients with Pompe disease. Proc Natl Acad Sci U
S A 1996;93:65e70.
42. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM,
Florence J, Groeneveld GJ, et al. A randomized study of
alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med
2010;362:1396e406.
43. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR,
et al. Clinical outcomes after long-term treatment with
alglucosidase alfa in infants and children with advanced
Pompe disease. Genet Med 2009;11:210e9.
44. Kikuchi T, Yang HW, Pennybacker M, Ichihara N, Mizutani M,
Van Hove JL, et al. Clinical and metabolic correction of
Pompe disease by enzyme therapy in acid maltase-deficient
quail. J Clin Invest 1998;101:827e33.
45. Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM,
Case LE, et al. The emerging phenotype of long-term survivors
with infantile Pompe disease. Genet Med 2012;14:800e10.
46. Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A,
Chen YT, et al. Nephrotic syndrome complicating alpha-
glucosidase replacement therapy for Pompe disease. Pediat-
rics 2004;114:e532e5.
47. Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS,
Ladda RL, et al. The impact of antibodies on clinical outcomes
in diseases treated with therapeutic protein: lessons learned
from infantile Pompe disease. Genet Med 2011;13:729e36.
48. Orsini JJ, Martin MM, Showers AL, Bodamer OA, Zhang XK,
Gelb MH, et al. Lysosomal storage disorder 4þ1 multiplex assay
for newborn screening using tandem mass spectrometry:
application to a small-scale population study for five lysosomal
storage disorders. Clin Chim Acta 2012;413:1270e3.
49. Parkinson-Lawrence E, Fuller M, Hopwood JJ, Meikle PJ,
Brooks DA. Immunochemistry of lysosomal storage disorders.
Clin Chem 2006;52:1660e8.
50. Millington DS, Sista R, Eckhardt A, Rouse J, Bali D, Goldberg R,
et al. Digital microfluidics: a future technology in the
newborn screening laboratory? Semin Perinatol 2010;34:
163e9.
51. Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A,
Clancy JP, et al. Early treatment with alglucosidase alpha
prolongs long-term survival of infants with Pompe disease.
Pediatr Res 2009;66:329e35.
52. Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK,
Keutzer J, et al. Pompe disease in infants: improving the
prognosis by newborn screening and early treatment. Pedi-
atrics 2009;124:e1116e25.
53. Chen LR, Chen CA, Chiu SN, Chien YH, Lee NC, Lin MT, et al.
Reversal of cardiac dysfunction after enzyme replacement in
patients with infantile-onset Pompe disease. J Pediatr 2009;
155:271e5.e2.
54. Chen CA, Chien YH, Hwu WL, Lee NC, Wang JK, Chen LR, et al.
Left ventricular geometry, global function, and dyssynchrony
in infants and children with pompe cardiomyopathy under-
going enzyme replacement therapy. J Card Fail 2011;17:
930e6.
Review of Pompe disease 22755. Kishnani PS, Howell RR. Pompe disease in infants and chil-
dren. J Pediatr 2004;144:S35e43.
56. Case LE, Beckemeyer AA, Kishnani PS. Infantile Pompe dis-
ease on ERT: update on clinical presentation, musculoskeletal
management, and exercise considerations. Am J Med Genet C
Semin Med Genet 2012;160:69e79.
57. DeRuisseau LR, Fuller DD, Qiu K, DeRuisseau KC,
Donnelly Jr WH, Mah C, et al. Neural deficits contribute to
respiratory insufficiency in Pompe disease. Proc Natl Acad Sci
U S A 2009;106:9419e24.
58. Gambetti P, DiMauro S, Baker L. Nervous system in Pompe’s
disease. Ultrastructure and biochemistry. J Neuropathol Exp
Neurol 1971;30:412e30.
59. Teng YT, Su WJ, Hou JW, Huang SF. Infantile-onset glycogen
storage disease type II (Pompe disease): report of a case with
genetic diagnosis and pathological findings. Chang Gung Med J
2004;27:379e84.
60. Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B,
Thurberg BL, et al. Enzyme replacement therapy in the mouse
model of Pompe disease. Mol Genet Metab 2003;80:159e69.
61. Ebbink BJ, Aarsen FK, van Gelder CM, van den Hout JM,
Weisglas-Kuperus N, Jaeken J, et al. Cognitive outcome of
patients with classic infantile Pompe disease receiving
enzyme therapy. Neurology 2012;78:1512e8.
62. Jones HN, Muller CW, Lin M, Banugaria SG, Case LE, Li JS,
et al. Oropharyngeal dysphagia in infants and children with
infantile Pompe disease. Dysphagia 2010;25:277e83.
63. van Gelder CM, van Capelle CI, Ebbink BJ, Moor-van
Nugteren I, van den Hout JM, Hakkesteegt MM, et al. Facial-
muscle weakness, speech disorders and dysphagia are com-
mon in patients with classic infantile Pompe disease treated
with enzyme therapy. J Inherit Metab Dis 2012;35:505e11.
64. Chien YH, Lee NC, Peng SF, Hwu WL. Brain development in
infantile-onset Pompe disease treated by enzyme replace-
ment therapy. Pediatr Res 2006;60:349e52.
65. Raben N, Ralston E, Chien YH, Baum R, Schreiner C, Hwu WL,
et al. Differences in the predominance of lysosomal and
autophagic pathologies between infants and adults with
Pompe disease: implications for therapy. Mol Genet Metab
2010;101:324e31.
66. Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC,
Bossen E, et al. Characterization of pre- and post-treatment
pathology after enzyme replacement therapy for Pompe dis-
ease. Lab Invest 2006;86:1208e20.
67. Banugaria SG, Patel TT, Mackey J, Das S, Amalfitano A,
Rosenberg AS, et al. Persistence of high sustained antibodies
to enzyme replacement therapy despite extensive immuno-
modulatory therapy in an infant with Pompe disease: need for
agents to target antibody-secreting plasma cells. Mol Genet
Metab 2012;105:677e80.
68. Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D,
Hershkovitz E, ChampionM, et al. Successful immune tolerance
induction to enzyme replacement therapy in CRIM-negative
infantile Pompe disease. Genet Med 2012;14:135e42.69. Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C,
et al. Predicting cross-reactive immunological material (CRIM)
status in Pompe disease using GAA mutations: lessons learned
from 10 years of clinical laboratory testing experience. Am J
Med Genet C Semin Med Genet 2012;160:40e9.
70. Hermans MM, de Graaff E, Kroos MA, Wisselaar HA,
Willemsen R, Oostra BA, et al. The conservative substitution
Asp-645e>Glu in lysosomal alpha-glucosidase affects trans-
port and phosphorylation of the enzyme in an adult patient
with glycogen-storage disease type II. Biochem J 1993;289:
687e93.
71. Zhu Y, Jiang JL, Gumlaw NK, Zhang J, Bercury SD, Ziegler RJ,
et al. Glycoengineered acid alpha-glucosidase with improved
efficacy at correcting the metabolic aberrations and motor
function deficits in a mouse model of Pompe disease. Mol
Ther 2009;17:954e63.
72. LeBowitz JH, Grubb JH, Maga JA, Schmiel DH, Vogler C,
Sly WS. Glycosylation-independent targeting enhances
enzyme delivery to lysosomes and decreases storage in
mucopolysaccharidosis type VII mice. Proc Natl Acad Sci U S A
2004;101:3083e8.
73. Maga JA, Zhou J, Kambampati R, Peng S, Wang X,
Bohnsack RN, et al. Glycosylation-independent lysosomal
targeting of acid alpha-glucosidase enhances muscle glycogen
clearance in pompe mice. J Biol Chem 2013;288:1428e38.
74. Parenti G. Treating lysosomal storage diseases with pharma-
cological chaperones: from concept to clinics. EMBO Mol Med
2009;1:268e79.
75. Khanna R, Flanagan JJ, Feng J, Soska R, Frascella M,
Pellegrino LJ, et al. The pharmacological chaperone AT2220
increases recombinant human acid alpha-glucosidase uptake
and glycogen reduction in a mouse model of Pompe disease.
PLoS One 2012;7:e40776.
76. Porto C, Ferrara MC, Meli M, Acampora E, Avolio V, Rosa M,
et al. Pharmacological enhancement of alpha-glucosidase by
the allosteric chaperone N-acetylcysteine. Mol Ther 2012;20:
2201e11.
77. Amalfitano A, McVie-Wylie AJ, Hu H, Dawson TL, Raben N,
Plotz P, et al. Systemic correction of the muscle disorder
glycogen storage disease type II after hepatic targeting of a
modified adenovirus vector encoding human acid-alpha-
glucosidase. Proc Natl Acad Sci U S A 1999;96:8861e6.
78. Sun B, Young SP, Li P, Di C, Brown T, Salva MZ, et al.
Correction of multiple striated muscles in murine Pompe
disease through adeno-associated virus-mediated gene ther-
apy. Mol Ther 2008;16:1366e71.
79. van Til NP, Stok M, Aerts Kaya FS, de Waard MC,
Farahbakhshian E, Visser TP, et al. Lentiviral gene therapy of
murine hematopoietic stem cells ameliorates the Pompe
disease phenotype. Blood 2010;115:5329e37.
80. Mah CS, Falk DJ, Germain SA, Kelley JS, Lewis MA,
Cloutier DA, et al. Gel-mediated delivery of AAV1 vectors
corrects ventilatory function in pompe mice with established
disease. Mol Ther 2010;18:502e10.
